The evolution of PR post COVID-19 Marketing News – Media Update

However, with the necessity of social distancing becoming the norm rather than the exception for the foreseeable future, PR professionals need to reimagine how they are going to effectively interact with the public and media to ensure that their clients' messaging reaches the intended target audience.What will remain the sameThe PR industry employs several tactics to disseminate their clients' messaging into the marketplace. These include:

"Previously, it was very easy to do so," says Schneider. "All PR firms had to do was to put on an event that would appeal to their audience, introduce them to the brand, give them goodie bags and free food and drinks; the invitees would be all too happy to post on social media about their experiences."

"However, it's tough to generate this same type of interaction between your brand and customers using digital. This means that PR firms will need to think out of the box in terms of creating the same type of buzz around a brand," adds Schneider.

The COVID-19 pandemic has made us all incredibly vulnerable. However, it is from this place of vulnerability that PR professionals will be able to innovate their industry to make it better than it was before.

The Digital School of Marketing is an online provider of accredited digital marketing education, which will allow you to get an edge over your competitors.

To find out more, visit http://www.digitalschoolofmarketing.co.za. You can also follow the Digital School of Marketing on Facebook, Twitter or on Instagram.

PR post COVID-19 Predictions for the public relations industry 2020 South African PR industry Public relations after Coronavirus

Read the original:

The evolution of PR post COVID-19 Marketing News - Media Update

The PNC Financial Services Group, Inc. (PNC) is primed for evolution with the beta value of 1.26 – The InvestChronicle

The PNC Financial Services Group, Inc. (PNC) is priced at $106.67 after the most recent trading session. At the very opening of the session, the stock price was $107.67 and reached a high price of $108.47, prior to closing the session it reached the value of $110.99. The stock touched a low price of $105.17.

The PNC Financial Services Group, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $161.79 on 12/30/19, with the lowest value was $79.41 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, The PNC Financial Services Group, Inc. shares are logging -34.07% during the 52-week period from high price, and 34.33% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $79.41 and $161.79.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 2.1 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the The PNC Financial Services Group, Inc. (PNC) recorded performance in the market was -33.18%, having the revenues showcasing -29.34% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 45.49B, as it employees total of 50017 workers.

During the last month, 10 analysts gave the The PNC Financial Services Group, Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 12 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 130.98, with a change in the price was noted -45.53. In a similar fashion, The PNC Financial Services Group, Inc. posted a movement of -29.91% for the period of last 100 days, recording 2,726,800 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for PNC is recording 0.89 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.89.

Raw Stochastic average of The PNC Financial Services Group, Inc. in the period of last 50 days is set at 36.09%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 78.43%. In the last 20 days, the companys Stochastic %K was 84.74% and its Stochastic %D was recorded 86.07%.

Considering, the past performance of The PNC Financial Services Group, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -33.18%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -28.07%, alongside a downfall of -21.11% for the period of the last 12 months. The shares increased approximately by 1.21% in the 7-day charts and went down by 7.28% in the period of the last 30 days. Common stock shares were lifted by -29.34% during last recorded quarter.

Read the original post:

The PNC Financial Services Group, Inc. (PNC) is primed for evolution with the beta value of 1.26 - The InvestChronicle

How Companies Should Prepare For The Evolution Of Work – ABCN’s Officing Today

The coronavirus revealed how many companies were unprepared for a pandemic, and remote working has become more important than ever. How can businesses prepare for another disruption?

First of all, having the infrastructure to support collaborative and video conferencing capabilities will be essential. This is particularly important as in the future, remote working will become a bigger part of the workforce and companies will need to be able to meet the needs of workers who continue to do so. On-site server-based video conferencing is limited to specific conference rooms, so moving towards cloud-based solutions is a good first step in supporting remote workers.

Physical meeting rooms will also need to be rethought as physical distancing requirements will likely be in place for the time being. Including stricter cleaning measures in shared spaces and encouraging workers to keep their distance from each other.

The Latest NewsDelivered To Your Inbox

Managing a secure workplace when remote working is also important. Cloud-based systems are the most convenient tools for these workers, but they can also pose security risks. This means companies will need to use powerful VPN services, encrypting files, using secure communication channels and implementing guidelines for physical computer security.

The impact of our current situation is going to change how we work forever, so it is up to companies to prepare for future pandemics and the changing workforce.

Originally posted here:

How Companies Should Prepare For The Evolution Of Work - ABCN's Officing Today

ABM Industries Incorporated (ABM) is primed for evolution with the beta value of 1.11 – The InvestChronicle

ABM Industries Incorporated (ABM) is priced at $34.49 after the most recent trading session. At the very opening of the session, the stock price was $35 and reached a high price of $35.74, prior to closing the session it reached the value of $35.95. The stock touched a low price of $34.26.

ABM Industries Incorporated had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $42.67 on 08/01/19, with the lowest value was $19.79 for the same time period, recorded on 03/24/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, ABM Industries Incorporated shares are logging -19.17% during the 52-week period from high price, and 74.27% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $19.79 and $42.67.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 1.43 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the ABM Industries Incorporated (ABM) recorded performance in the market was -8.54%, having the revenues showcasing -11.29% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.31B, as it employees total of 140000 workers.

During the last month, 4 analysts gave the ABM Industries Incorporated a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 2 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 34.11, with a change in the price was noted -3.17. In a similar fashion, ABM Industries Incorporated posted a movement of -8.42% for the period of last 100 days, recording 484,330 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for ABM is recording 0.55 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.51.

Raw Stochastic average of ABM Industries Incorporated in the period of last 50 days is set at 75.69%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 85.86%. In the last 20 days, the companys Stochastic %K was 92.95% and its Stochastic %D was recorded 94.01%.

Lets take a glance in the erstwhile performances of ABM Industries Incorporated, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -8.54%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -7.71%, alongside a downfall of -5.84% for the period of the last 12 months. The shares increased approximately by 4.44% in the 7-day charts and went down by 10.72% in the period of the last 30 days. Common stock shares were lifted by -11.29% during last recorded quarter.

Read more from the original source:

ABM Industries Incorporated (ABM) is primed for evolution with the beta value of 1.11 - The InvestChronicle

Gilead Sciences, Inc. (GILD) is primed for evolution with the beta value of 0.71 – The InvestChronicle

Gilead Sciences, Inc. (GILD) is priced at $84.00 after the most recent trading session. At the very opening of the session, the stock price was $85.47 and reached a high price of $85.67, prior to closing the session it reached the value of $83.14. The stock touched a low price of $81.33.

Gilead Sciences, Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $85.97 on 03/19/20, with the lowest value was $60.89 for the same time period, recorded on 10/03/19.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Gilead Sciences, Inc. shares are logging -2.29% during the 52-week period from high price, and 37.95% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $60.89 and $85.97.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 38.89 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Gilead Sciences, Inc. (GILD) recorded performance in the market was 29.27%, having the revenues showcasing 31.19% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 110.56B, as it employees total of 11800 workers.

During the last month, 11 analysts gave the Gilead Sciences, Inc. a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 12 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 3 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 70.53, with a change in the price was noted +18.07. In a similar fashion, Gilead Sciences, Inc. posted a movement of +27.41% for the period of last 100 days, recording 19,211,229 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for GILD is recording 1.09 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.98.

Raw Stochastic average of Gilead Sciences, Inc. in the period of last 50 days is set at 90.86%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 87.58%. In the last 20 days, the companys Stochastic %K was 73.26% and its Stochastic %D was recorded 64.24%.

If we look into the earlier routines of Gilead Sciences, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 29.27%. Additionally, trading for the stock in the period of the last six months notably improved by 32.39%, alongside a boost of 29.49% for the period of the last 12 months. The shares increased approximately by 1.80% in the 7-day charts and went down by 8.00% in the period of the last 30 days. Common stock shares were driven by 31.19% during last recorded quarter.

Read more:

Gilead Sciences, Inc. (GILD) is primed for evolution with the beta value of 0.71 - The InvestChronicle

Fastenal Company (FAST) is primed for evolution with the beta value of 1.14 – The InvestChronicle

Lets start up with the current stock price of Fastenal Company (FAST), which is $36.22 to be very precise. The Stock rose vividly during the last session to $36.64 after opening rate of $36.47 while the lowest price it went was recorded $35.88 before closing at $36.74.

Fastenal Company had a pretty favorable run when it comes to the market performance. The 1-year high price for the companys stock is recorded $39.31 on 02/20/20, with the lowest value was $26.72 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Fastenal Company shares are logging -7.85% during the 52-week period from high price, and 35.58% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $26.72 and $39.31.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 5.49 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Fastenal Company (FAST) recorded performance in the market was -1.98%, having the revenues showcasing 0.22% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 20.70B, as it employees total of 22131 workers.

During the last month, 2 analysts gave the Fastenal Company a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 11 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 35.25, with a change in the price was noted +0.94. In a similar fashion, Fastenal Company posted a movement of +2.66% for the period of last 100 days, recording 5,133,671 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for FAST is recording 0.17 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.17.

Raw Stochastic average of Fastenal Company in the period of last 50 days is set at 75.50%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 78.03%. In the last 20 days, the companys Stochastic %K was 83.40% and its Stochastic %D was recorded 87.85%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -1.98%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -1.39%, alongside a boost of 4.58% for the period of the last 12 months. The shares increased approximately by 4.53% in the 7-day charts and went down by 3.72% in the period of the last 30 days. Common stock shares were driven by 0.22% during last recorded quarter.

Continue reading here:

Fastenal Company (FAST) is primed for evolution with the beta value of 1.14 - The InvestChronicle

CymaBay Therapeutics, Inc. (CBAY) is primed for evolution with the beta value of 1.03 – The InvestChronicle

CymaBay Therapeutics, Inc. (CBAY) is priced at $1.80 after the most recent trading session. At the very opening of the session, the stock price was $1.83 and reached a high price of $1.9, prior to closing the session it reached the value of $1.82. The stock touched a low price of $1.8.

CymaBay Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $13.55 on 05/15/19, with the lowest value was $1.21 for the same time period, recorded on 03/18/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, CymaBay Therapeutics, Inc. shares are logging -86.68% during the 52-week period from high price, and 49.17% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $1.21 and $13.55.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 528432 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CymaBay Therapeutics, Inc. (CBAY) recorded performance in the market was -7.14%, having the revenues showcasing -2.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 122.96M, as it employees total of 24 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.7011, with a change in the price was noted +0.1800. In a similar fashion, CymaBay Therapeutics, Inc. posted a movement of +10.84% for the period of last 100 days, recording 1,546,513 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for CBAY is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

Raw Stochastic average of CymaBay Therapeutics, Inc. in the period of last 50 days is set at 91.30%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 88.46%. In the last 20 days, the companys Stochastic %K was 94.64% and its Stochastic %D was recorded 92.16%.

Bearing in mind the latest performance of CymaBay Therapeutics, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -7.14%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -59.91%, alongside a downfall of -85.79% for the period of the last 12 months. The shares increased approximately by 12.54% in the 7-day charts and went down by 15.92% in the period of the last 30 days. Common stock shares were lifted by -2.15% during last recorded quarter.

Read this article:

CymaBay Therapeutics, Inc. (CBAY) is primed for evolution with the beta value of 1.03 - The InvestChronicle

COVID 2.0: The deadly evolution of misinformation – Sky News Australia

Evidence is mounting that the killer coronavirus has already mutated into dozens of new strains, but the dire warnings of scientists appear to be falling, yet again, on the deaf ears of those coordinating the pandemic.Several studies have confirmed the mutation phenomenon is a reality for the Wuhan virus but the World Health Organization appears to be unwilling to draw conclusions from these early studies.The official line is still: there is no evidence that the virus has been changing.Viruses are incredibly complex, especially the novel variety, so caution is understandable.A virus is neither alive nor dead and it continues existing through a process of replication which inevitably becomes error-ridden.Those mistakes in genetic sequencing become mutations.This is a function of existence which is both unavoidable and the very reason species evolve.It is simply untrue to suggest that there is no evidence the virus has been changing and the WHOs stance has been puzzling to scientists who study viruses and understand how they evolve.According to epidemiologist Erik Volz at Imperial College London, all viruses mutate and COVID-19 is no exception.I think its a fact that there are two strains, he said.Its normal for viruses to undergo evolution when they are transmitted to a new host.University of Reading biomedical scientist Ian Jones reveals a virus mutates half a dozen times each time it replicates in its victims respiratory tract.There is plenty of evidence the virus is changing but the WHO is reluctant to accept this well-documented scientific fact.And why does it matter?Different strains can vastly change the direction of this pandemic. Strains can be more aggressive, contain a more potent viral load, as scientists describe it, and even target specific demographics more ferociously.All of which could have vast implications for isolation policies such as the effectiveness of herd immunity or the need for people with certain medical conditions to isolate for longer periods of time.Researchers in India believe they have discovered evidence of at least 10 different strains.National Institute of Biomedical Genomics researcher Partha Majumder believes the Wuhan virus started off as an ancestral O-type strain before splitting off into several other versions.That original strain, now dubbed SARS-CoV2, appeared to be a bolstered version of the old SARS virus which had muted to have better transmission rates.To live, a virus must propagate by infecting other animals, he wrote.A mutation usually disables the virus from transmitting itself.However, some mutations enable the virus to transmit more efficiently and infect more persons.Such mutant viruses increase the frequency of transmission and sometimes completely replace the original type of the virus. The SARS-CoV2 is doing just that."Concerningly one strain, A2a, accounted for nearly half of test samples making it the most dominant strain the Indian team encountered.As scientists from different fields begin to pool their experiences with the virus it is becoming clearer that specific demographics are more at risk to the mutated strains.Obesity and age appear to be the largest and most obvious risk factors, but it has emerged that at least some strains of the Wuhan virus are triggering stokes in people outside of those demographic confines.Researchers at the New England Journal of Medicine are probing the deaths of five coronavirus patients, all aged under 50, who suffered large vessel strokes in a two week period.Of the five, one patient died, one is in intensive care and three are in post-stroke recovery.The concern for researchers were the near-complete lack of symptoms for all individuals.It appears that one strain of the coronavirus targets large blood vessels in a manner similar to what happened with the first SARS outbreak.Moreover, large-vessel stroke was reported in association with the 2004 SARS-CoV-1 outbreak in Singapore, the researchers wrote.Coagulopathy and vascular endothelial dysfunction have been proposed as complications of Covid-19.3 The association between large-vessel stroke and Covid-19 in young patients requires further investigation.It is disappointing that senior health officials at the WHO have failed to address any of the above concerns.While the scientific community does not share consensus issuing absolutist statements suggesting the virus cannot mutate, or cannot be transmitted from person to person, is dangerous and could have very deadly consequences.As more is learned about the Wuhan virus the real experts must be brought into the conversation and our leaders must be cautious about taking advice from an organisation which has got so much wrong.

See original here:

COVID 2.0: The deadly evolution of misinformation - Sky News Australia

Omnicom Group Inc. (OMC) is primed for evolution with the beta value of 0.73 – The InvestChronicle

Omnicom Group Inc. (OMC) is priced at $55.87 after the most recent trading session. At the very opening of the session, the stock price was $56.02 and reached a high price of $56.32, prior to closing the session it reached the value of $57.03. The stock touched a low price of $55.01.

Omnicom Group Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $85.05 on 07/16/19, with the lowest value was $46.37 for the same time period, recorded on 03/23/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Omnicom Group Inc. shares are logging -34.31% during the 52-week period from high price, and 20.49% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $46.37 and $85.05.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 851928 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Omnicom Group Inc. (OMC) recorded performance in the market was -29.61%, having the revenues showcasing -24.95% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 12.45B, as it employees total of 70000 workers.

During the last month, 3 analysts gave the Omnicom Group Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 3 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 68.82, with a change in the price was noted -23.89. In a similar fashion, Omnicom Group Inc. posted a movement of -29.88% for the period of last 100 days, recording 2,415,393 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for OMC is recording 1.85 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.62.

Raw Stochastic average of Omnicom Group Inc. in the period of last 50 days is set at 30.09%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 50.27%. In the last 20 days, the companys Stochastic %K was 66.23% and its Stochastic %D was recorded 74.33%.

Lets take a glance in the erstwhile performances of Omnicom Group Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -29.61%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -26.12%, alongside a downfall of -27.78% for the period of the last 12 months. The shares increased approximately by 9.37% in the 7-day charts and went up by 10.76% in the period of the last 30 days. Common stock shares were lifted by -24.95% during last recorded quarter.

View original post here:

Omnicom Group Inc. (OMC) is primed for evolution with the beta value of 0.73 - The InvestChronicle

Genius Brands International, Inc. (GNUS) is primed for evolution with the beta value of 0.20 – The InvestChronicle

Lets start up with the current stock price of Genius Brands International, Inc. (GNUS), which is $0.32 to be very precise. The Stock rose vividly during the last session to $0.34 after opening rate of $0.31 while the lowest price it went was recorded $0.31 before closing at $0.30.

Genius Brands International, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $2.33 on 05/08/19, with the lowest value was $0.05 for the same time period, recorded on 03/12/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Genius Brands International, Inc. shares are logging -86.27% during the 52-week period from high price, and 520.16% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.05 and $2.33.

The companys shares, operating in the sector of services managed to top a trading volume set approximately around 1.61 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Genius Brands International, Inc. (GNUS) recorded performance in the market was 9.68%, having the revenues showcasing -7.23% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 8.68M, as it employees total of 19 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.2823, with a change in the price was noted +0.0282. In a similar fashion, Genius Brands International, Inc. posted a movement of +9.42% for the period of last 100 days, recording 718,849 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for GNUS is recording 0.60 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.34.

Raw Stochastic average of Genius Brands International, Inc. in the period of last 50 days is set at 69.25%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 75.63%. In the last 20 days, the companys Stochastic %K was 61.86% and its Stochastic %D was recorded 54.88%.

Considering, the past performance of Genius Brands International, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be pessimistic, given the fact the metric is recording 9.68%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -56.37%, alongside a downfall of -84.66% for the period of the last 12 months. The shares increased approximately by 0.28% in the 7-day charts and went up by 14.03% in the period of the last 30 days. Common stock shares were lifted by -7.23% during last recorded quarter.

Here is the original post:

Genius Brands International, Inc. (GNUS) is primed for evolution with the beta value of 0.20 - The InvestChronicle

Ferro Corporation (FOE) is primed for evolution with the beta value of 1.82 – The InvestChronicle

Ferro Corporation (FOE) is priced at $10.48 after the most recent trading session. At the very opening of the session, the stock price was $10.23 and reached a high price of $10.73, prior to closing the session it reached the value of $9.78. The stock touched a low price of $10.2.

Ferro Corporation had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $18.03 on 04/30/19, with the lowest value was $7.52 for the same time period, recorded on 04/03/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Ferro Corporation shares are logging -41.89% during the 52-week period from high price, and 39.36% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $7.52 and $18.03.

The companys shares, operating in the sector of basic materials managed to top a trading volume set approximately around 1.24 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Ferro Corporation (FOE) recorded performance in the market was -29.33%, having the revenues showcasing -25.88% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 860.23M, as it employees total of 5922 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 12.36, with a change in the price was noted -3.99. In a similar fashion, Ferro Corporation posted a movement of -27.57% for the period of last 100 days, recording 864,183 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for FOE is recording 2.24 at the time of this writing. In addition, long term Debt to Equity ratio is set at 2.22.

Raw Stochastic average of Ferro Corporation in the period of last 50 days is set at 39.78%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 92.07%. In the last 20 days, the companys Stochastic %K was 78.32% and its Stochastic %D was recorded 66.57%.

Lets take a glance in the erstwhile performances of Ferro Corporation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -29.33%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -8.87%, alongside a downfall of -41.35% for the period of the last 12 months. The shares increased approximately by 10.94% in the 7-day charts and went up by 17.36% in the period of the last 30 days. Common stock shares were lifted by -25.88% during last recorded quarter.

Here is the original post:

Ferro Corporation (FOE) is primed for evolution with the beta value of 1.82 - The InvestChronicle

Xenia Hotels & Resorts, Inc. (XHR) is primed for evolution with the beta value of 1.18 – The InvestChronicle

Lets start up with the current stock price of Xenia Hotels & Resorts, Inc. (XHR), which is $10.22 to be very precise. The Stock rose vividly during the last session to $10.51 after opening rate of $9.87 while the lowest price it went was recorded $9.87 before closing at $9.46.

Xenia Hotels & Resorts, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $23.33 on 05/06/19, with the lowest value was $6.28 for the same time period, recorded on 03/19/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Xenia Hotels & Resorts, Inc. shares are logging -56.19% during the 52-week period from high price, and 62.74% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $6.28 and $23.33.

The companys shares, operating in the sector of financial managed to top a trading volume set approximately around 1.08 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Xenia Hotels & Resorts, Inc. (XHR) recorded performance in the market was -52.71%, having the revenues showcasing -47.46% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.15B, as it employees total of 48 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 15.98, with a change in the price was noted -10.57. In a similar fashion, Xenia Hotels & Resorts, Inc. posted a movement of -50.84% for the period of last 100 days, recording 900,517 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for XHR is recording 0.74 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.74.

Raw Stochastic average of Xenia Hotels & Resorts, Inc. in the period of last 50 days is set at 30.05%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 83.97%. In the last 20 days, the companys Stochastic %K was 57.26% and its Stochastic %D was recorded 36.86%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -52.71%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -51.03%, alongside a downfall of -52.79% for the period of the last 12 months. The shares increased approximately by 2.50% in the 7-day charts and went up by 24.48% in the period of the last 30 days. Common stock shares were lifted by -47.46% during last recorded quarter.

See original here:

Xenia Hotels & Resorts, Inc. (XHR) is primed for evolution with the beta value of 1.18 - The InvestChronicle

Seelos Therapeutics, Inc. (SEEL) is primed for evolution with the beta value of 1.14 – The InvestChronicle

Lets start up with the current stock price of Seelos Therapeutics, Inc. (SEEL), which is $0.59 to be very precise. The Stock rose vividly during the last session to $0.61 after opening rate of $0.54 while the lowest price it went was recorded $0.54 before closing at $0.53.

Seelos Therapeutics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $3.06 on 04/30/19, with the lowest value was $0.42 for the same time period, recorded on 04/02/20.

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Seelos Therapeutics, Inc. shares are logging -80.67% during the 52-week period from high price, and 41.00% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $0.42 and $3.06.

The companys shares, operating in the sector of healthcare managed to top a trading volume set approximately around 1.32 million for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Seelos Therapeutics, Inc. (SEEL) recorded performance in the market was -55.86%, having the revenues showcasing -49.01% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 25.56M, as it employees total of 6 workers.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.9309, with a change in the price was noted -0.3505. In a similar fashion, Seelos Therapeutics, Inc. posted a movement of -37.21% for the period of last 100 days, recording 784,184 in trading volumes.

Raw Stochastic average of Seelos Therapeutics, Inc. in the period of last 50 days is set at 22.92%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 90.29%. In the last 20 days, the companys Stochastic %K was 83.13% and its Stochastic %D was recorded 72.72%.

Considering, the past performance of Seelos Therapeutics, Inc., multiple moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -55.86%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -34.39%, alongside a downfall of -80.35% for the period of the last 12 months. The shares increased approximately by 1.40% in the 7-day charts and went up by 25.85% in the period of the last 30 days. Common stock shares were lifted by -49.01% during last recorded quarter.

Continue reading here:

Seelos Therapeutics, Inc. (SEEL) is primed for evolution with the beta value of 1.14 - The InvestChronicle

The Idea of the Brain explores the evolution of neuroscience – Science News

The Idea of the BrainMatthew CobbBasic Books, $32

Neuroscientistslove a good metaphor. Through the years, plumbing, telegraph wires and computershave all been enlisted to help explain how the brain operates, neurobiologistand historian Matthew Cobb writes in The Idea of the Brain. And like anymetaphor, those approximations all fall short.

Cobb leads afascinating tour of how concepts of the brain have morphed over time. Hiswriting is clear, thoughtful and, when called for, funny. He describesexperiments by neurosurgeon Wilder Penfield, who zapped awake patients brainswith electricity to provoke reactions. Zapping certain places consistentlydredged up memories, which Cobb calls oneiric experiences. His footnote onthe term: Look it up. Its exactly theright word. I did, and it was.

Cobb runs though the history of certain concepts used to explain how the brain works, including electricity, evolution andneurons. Next comes a section on the present, which includes discussions ofmemory, circuits and consciousness. Cobb offers tastes of the latest research, anda heavy dose of realism. Memory studieshave made progress, but we are still far from understanding what ishappening when we remember, Cobb writes. Despite big efforts, we still onlydimly understand what is going on when we see.Our understanding of how antidepressants work? Virtually non-existent.

Headlines and summaries of the latest Science News articles, delivered to your inbox

This real talk isrefreshing, and Cobb uses it to great effect toargue that neuroscience is stymied. There have been many similarmoments in the past, when brain researchers became uncertain about how toproceed, he writes. Scientists have amassed an impressive stockpile of brain facts,but a true understanding of how the brain works eludes us.

Dont expect a computer metaphor to help. Like a computer, the brainsmain job is to process information. But some experts argue that because brains are biologicalthey evolved within the vagaries of a bodythey operate in ways that a machine doesnt (SN: 8/23/16).

Cobb reckonsthat, among other reasons, the mere existenceof such objections is a harbinger of the end of the computer metaphor.But that doesnt mean the comparison was awaste. Metaphors clarify thoughts, he writes, and scientists would do well toponder what might replace the concept.

He ends the book with a creative exercise inlooking ahead to what the future might hold. The possibilities include the creation of conscious machines, or even having toaccept that there is no brain theory to be found. Still, our currentignorance should not be viewed as a sign of defeat, Cobb writes, but as achallenge.

Buy The Idea of the Brain from Amazon.com.Science Newsis a participant in the Amazon Services LLC Associates Program. Please see ourFAQfor more details.

See the original post here:

The Idea of the Brain explores the evolution of neuroscience - Science News

‘Extraction’ and the Evolution of Chris Hemsworth – Hollywood Reporter

Extraction comes from the Russos production company AGBO, and is its second feature following last falls 21 Bridges (2019), starring Chadwick Boseman. So far, the Russos have primarily used the film side of AGBO as a chance to develop non-superhero stories with a troupe of MCU actors. With the exception of the upcoming Sundance horror hit, Relic, also produced by Jake Gyllenhaal, AGBO has placed its development attention on mid-budget action thrillers, a source of lifeblood for theatrical experiences before the superhero boom of the 2000s. The production companys next film, Cherry, also directed by the Russo Brothers, stars Tom Holland as a bank robber with an opioid addiction. AGBO also has a remake of The Thomas Crown Affair on the docket, and it wouldnt come as a surprise to see a Marvel star at the front of that film as well. There is an interest at the production company, it would seem, in finding a new way to take these superhero actors who possess the kind of star power that would have made them bigger than any one character in the '90s, and pair them with old-school premises, all for a reasonable price.

Extraction revels in the kind of old-school action of the '90s, boasting crazy stunts and a surplus of gunplay. While the plot is reminiscent of Man on Fire (1987) and (2004), and Hargraves direction is sure to draw fair comparisons to the John Wick franchise, Extraction is even simpler than that. It eschews world building of the Keanu Reeves franchise for the kind of pure action movie spectacle that those raised on the films of Stallone and Schwarzenegger might expect. But Hemsworth is different from the leading men of old, and even while placed within a story that feels like a throwback, his performance is uniquely modern in terms of our expectations of the action lead. Hemsworths mercenary, Tyler Rake, isnt entirely unlike characters weve seen before, men with military backgrounds and tragic pasts who are forced to serve as both protector and caretaker. But whereas so many of these types of characters begin as emotionally detached at best, and assholes at worst, Rake is likable without trying to come across as so. Theres an inherent charisma to the character, and his relationship with 14-year-old Ovi (Rudhraksh Jaiswal), while not close initially, isnt without some sense of kinship, manifested in Rakes early referral to him as mate and his consideration of him as more than a package but a person. Whats interesting about Hemsworths performance here is that the role of Tyler Rake is not so different from the kind of roles he was offered at the start of his career. Yet, his filmography has given him the tools to transform his inherent good looks and stoicism into something more compelling and worthy of the star power he now possesses.

Its easy to imagine seeing Extraction in theaters, as the film certainly looks theatrical, and features action and set pieces that would look incredible on a big screen. But the film stands to get more eyes on it on Netflix than it would in the theatrical marketplace, and this would have been true before the COVID-19 pandemic. Boasting a strong performance from Boseman,21 Bridges, a weaker film than Extraction, made $50 million on a $33 million budget. Not a big loss for STXFilms, but its a prime example of a film that would have undoubtedly found a larger audience and served Bosemans star power better on Netflix. As we see cinemas become increasingly event-driven, with audiences more willing to shell out for ticket prices only for the biggest films, it becomes harder for actors to attract general audiences for anything beyond the superheroes they play. Just because everyone turned out to see Boseman as Black Panther, doesnt mean that theyll do the same to see him play an NYC cop. But with streaming services, and nonevent level expectations that come with those releases, actors have a better chance to see their star power utilized in the same way those marquee names of the '90s did. While "lets watch the new Thor" is far more likely to be heard than "lets watch the new Hemsworth" at cinemas, the latter statement is far more likely when considering the age of streaming.

Hemsworth is the perfect example through which to consider the wane of traditional star power and its newfound potential. Before landing the career-changing role of Thor in Kenneth Branaghs 2011 film, Hemsworths filmography consisted of a brief role as George Kirk in Star Trek (2009), and small supporting roles in horror movies A Perfect Getaway (2009) and The Cabin in the Woods (2011), which showed early range but didnt necessarily suggest a leading man. Thor and The Avengers, gave him weightier material, including a powerful scene that saw him face off against Anthony Hopkins, but the takeaway from those performances resulted mostly in roles that did little to set him apart from Hollywood's then-current crop of blond leading men. Red Dawn (2012) and Snow White and the Huntsman (2012) were the most immediate signs that Hemsworth's portrayal of a superhero didnt automatically result in a box office following. Snow White was a box office success, but as the sequel, The Huntsman: Winters War, eventually proved, the success of the first had more to do with an attachment to the fairy tale, and a great trailer, than any real interest in Hemsworth as a YA romance styled sword and sorcery hero.

The most important step in Hemsworths post-Thor career was playing James Hunt in Ron Howards Rush (2013). Not entirely a 180 from Thor, Hemsworths charm and swagger, fully on display here, also manifested something deeper, a steely-eyed focus that suggested not only a grand inner monologue but a stormy emotionality. Theres a sense of drive in Hemsworths performance as Hunt, a conscious desire to cover up a formidable and dangerous feeling of inferiority. Further performances in Michael Manns Blackhat (2015) and Howards In the Heart of the Sea (2015), neither critical or box office darlings, showcased the potential of an actor who never seemed quite comfortable in the role of jock or eye candy. In terms of the latter, Hemsworth managed to push against this type of casting and poke fun at himself by entering the realm of comedy, first with Vacation (2015), and then with Ghostbusters (2016). Again, neither film was a critical or box office success, despite Hemsworth being genuinely funny, but they sharpened the tools that took him to his next venture, and allowed him to bring more of himself and comedy to Thor by the time he reached the third entry,Thor: Ragnarok (2017), which revitalized his interest in the role.

Hemsworth tapped into his dark side as a charismatic cult leader, Billy Lee, in the criminally underseen Bad Times at the El Royale (2019), arguably his best performance, and channeled Roger Moore in Men in Black: International. Whats interesting about his career is that despite very little box office success outside of his role as Thor, Hemsworth shows the most consistent evolution as a performer of his Avengers co-stars. Theres never a sense that hes simply settled into the comfort of being an actor known for one type of role, even if he does find himself appearing in some genres more frequently than others. Theres a quality to Hemsworth that makes him comparable to fellow Aussie Mel Gibson, before his directorial fame with Braveheart (1995), and the controversies that have marred the latter part of his career. Theres a quality the two actors share, not only because they both found their fame in franchises, Thor and Mad Max, but because they also managed to deliver engaging, genre-crossing performances in films that werent box office sensations but showed a consistent development of craft. Most important, Hemsworth, like Gibson, is an action hero whose tears are believable. It may seem like a small thing, but theres a vulnerability to Hemsworth that allows him to come across as genuine and personable, an essential quality when so much of action films are built around artifice and grandeur. His ability to convincingly play the vulnerable hero made him the MVP of Infinity War, and its what allows for the investment in Extraction. Tyler Rake is a role Hemsworth could have been cast in immediately after Thor, but he wouldnt be nearly as effective as he is in it without the decade of refinement.

Star power will likely never translate into box office receipts the way it used to, but that doesnt mean the concept is gone. It seems likely that it will simply translate into a new format. While Netflix is typically hush hush on how its features perform, it wouldn't be a surprise to see the streaming service champion the film as one of its biggest hits, especially with households craving new content while under quarantine. Turning star power into streaming service currency seems like a realistic outcome not only for AGBO, which has yet to finalize a distributor for Cherry, but for a number of studios still looking to keep mid-budget films alive, and agents who still bet on the power of a name. Extraction isnt the first of Netflixs big-budget releases, which include Six Underground (2019) and Bright (2017), but it is arguably the best, and the best argument for selling films based on names. Chris Hemsworth may not get his name on theater marquees for opening days, but his name is certainly going to populate a lot of Netflix queues over the weekend.

View post:

'Extraction' and the Evolution of Chris Hemsworth - Hollywood Reporter

Hayley Williams’ Evolution From Paramore To ‘Petals For Armor’ – MTV.com

By Grant Sharples

Paramore, despite no longer making pop-punk music, have become one of the quintessential bands in the genre. Their early catchy, cathartic choruses on songs such as crushcrushcrush and Thats What You Get are representative of the entire Warped-Tour era of the 2000s. But although this heavily male-dominated, often misogynistic scene consisted of plenty of bands wishing for their ex-girlfriends deaths amid other violent fantasies, Paramore defied its patriarchal penchant.

Ringleader Hayley Williams has reckoned with her own share of internalized misogyny and eventually decided to stop performing Misery Business live because of its infamous lyric Once a whore, youre nothing more. She has brought that critical self-analysis to her own solo career, which shes spent 2020 rolling out across both music and visuals.

When record executives wanted to make Williams a solo artist at age 14, she refused and started a pop-punk band instead. Unlike the catalogs of many of her bands peers, each entry in Paramores discography has expanded upon and differentiated itself from what preceded it, evolving from hard guitars to more mature motifs and eventually an 80s synth-pop sound. Now, with the impending release of Williamss debut solo album, Petals for Armor, she has evolved yet again, showing a propensity for minimalist indie-pop with hints of funk, folk, and, of course, emo. Williams has been somewhat of a musical chameleon, constantly shapeshifting and adopting new sounds, mastering one only to abandon it and try another.

Though Petals for Armor is due out in full May 8, Williams has preceded it with two exploratory EPs. The 10 songs released so far and what came before them showcase how far shes come in the past 15 years.

Read the rest here:

Hayley Williams' Evolution From Paramore To 'Petals For Armor' - MTV.com

Evolution of the Third-Party Funder – Lexology

This chapter explores investorstate dispute settlement (ISDS) to reveal the origins of that now ubiquitous feature of investment treaty arbitration the third-party funder. Where does it come from? How did it get here? And how did it spread so quickly? To some, a headache to others, a cure. In examining the past we may even get a glimpse of the future of this unusual and resilient facet of ISDS.

As with all good investigations that seek to identify what was to explain what has come to be, it is proposed that there are categories with specific characteristics of their age that reveal different stages of development. Each of these categories are designated ages specific to the evolution of the third-party funder, summarised in the following table:

I The Pre-Industry age

Third-party funding as a concept has existed for hundreds of years, and likely more. Despite what critics of third-party funding may say, it has its origins in access to justice. Jeremy Bentham wrote exhaustively on the topic of access to justice in the 1700s in the furtherance of ideas such as utilitarianism and distributive justice, and worked tirelessly for the repeal of champerty and maintenance laws in place since medieval times. The cost of access to justice has long been high in most legal jurisdictions, and without third-party funding good claims were often defeated by deep pockets. The fear that vulnerable people could be used as puppets in staged legal battles between wealthy land owners was not sufficient to deny access to justice for the majority of the population. It was inconsistent with what Bentham defined as the 'fundamental axiom' of his philosophy: the principle that 'it is the greatest happiness of the greatest number that is the measure of right and wrong'.

Since then, very slowly, champerty and maintenance laws or their equivalents in most legal jurisdictions have been diluted or repealed in whole or in part. However, this is, in short, the philosophical origins of access to justice and third-party funding, not third-party funders. Third-party funders with a specific mandate to invest in disputes are a relatively recent phenomenon. Research suggests that prior to 2005, there were few types of third-party funders with the dedicated purpose of investing in claims, let alone a third-party funding industry.2 Although third-party funding as an investment opportunity existed, it was relatively low-profile and characterised by an infrequent ad hoc nature. There is debate as to whether it evolved in Australia (long considered the birth place of third-party funding in the common law world) or Germany as an offshoot from a highly developed form of legal insurance. There is little doubt that, during this pre-industry age, types of third-party funders existed in both these jurisdictions. However, the type of third-party funder unconnected with a claimant prior to the beginning of a dispute (i.e., not premium-based legal cost insurance) with the ability to allow for complete, or near complete, cost-risk transfer in exchange for sharing damages to advance a claim, the essence of the modern day third-party funder is likely to have arisen in common law jurisdictions. Why? Cost. The cost of third-party funding in most common law jurisdictions, owing to the nature of their litigation proceedings, is generally higher than civil law jurisdictions. In common law jurisdictions, it was and is for many as the former Irish Judge Sir James Mathew has said, that 'justice is open to all, like the Ritz Hotel.'3

A third-party funder during this pre-industry age, from the early 1990s to the early 2000s, was unlikely to have many disputes specialist lawyers working for it let alone ISDS specialists. They would have likely been characterised by insurance and investment experience; it would have undoubtedly required a high appetite for risk. Financial markets at this time were running hot and cold. Surplus funds designated for high-risk investment turned to third-party funding as an uncorrelated asset class.4 As a consequence, and from mostly anecdotal evidence, commercial terms ran high. Terms as high as 80 per cent of the damages have been seen and were likely common, embedded in questionably enforceable contracts.

In parallel to this development, the notion of beneficial ownership of proceeds and control was being revisited at the ISDS level as exemplified by CSOB Bank v. Slovak Republic, where the tribunal found that:

The issue at stake in this dispute was nationality and control from financing parties. Such cases involving beneficial ownership of the proceeds of a claim and control set the scene for revisiting this issue with third-party funders at a subsequent stage.

II The Industry Age

In this period, the viability of third-party funding as not just an ad hoc investment opportunity but as an industry started to take shape. The evolution was not, of course, uniform; some jurisdictions advanced faster than others. In Europe, the United Kingdom was where many third-party funders began to most resemble modern day third-party funders. Third-party funding contracts were mostly imported and worked on from non-recourse financing practices, and a small body of law began to develop. However, from the decision in Arkin v. Borchard Lines Ltd (2005), a shift occurred in the United Kingdom. It is a decision that gave rise to what has since been interpreted as the principle that a funder could be held liable in adverse costs for a failed claim up to the amount that it invested into that claim: the 'Arkin cap', which has more recently come under review from the 2017 decision in Bailey v. GlaxoSmithkline UK Ltd. For some, Arkin exposed a potential liability that would deter investors in third-party funding. For others, Arkin provided reassuring clarity. A known unknown became clearer, and from it contractual risk sharing mechanisms could be forged and business models engineered. Arkin provided the bedrock on which a new industry could be founded. It heralded the first paradigm shift of third-party funding from isolated investment opportunity to the creation of third-party funding as a viable business model that would give rise to the burgeoning industry that it is today.

During this time, third-party funding was still mostly concentrated on litigation but, as with all developing industries, satellite opportunities spiralled from it to create third-party funding brokers.6 A satellite industry was formed by those who had worked on raising financing on an ad hoc basis for claims during the pre-industry age those individuals with ability and foresight but who had neither the means nor arguably the appetite for third-party funding of disputes. Brokers accounted for the majority of third-party funding opportunities for the nascent third-party funder during the industry age. They paved the way through competition and legitimisation for not only a standardisation of terms but the expansion of third-party funding into commercial arbitration. As more funders came on to the market, the need for more investment opportunities expanded. In exchange for a tempering of industry terms to what is still often seen today the greater of three times the investment or 30 per cent of the damages brokers sought to increase the number of investment opportunities for these hungry third-party funders. International commercial arbitration was a natural choice. Rooted in practices not too dissimilar to what the third-party funding industry were used to, the leap was not one of faith but of logic.

The nature of international commercial arbitration is more private than either litigation or ISDS. The confidentiality of the proceedings and the privacy of the parties allowed third-party funders to revert to a more creative financial space. How a private party to private proceedings financed its dispute was not the purview of the tribunal in commercial arbitration. This allowed funders to focus more on creative financial solutions than legal issues in respect of access to justice and any form of associated liability for costs. As third-party funders were not considered party to the arbitration agreement, they were not exposed to the same liability as they might be during domestic litigation as with Arkin in the United Kingdom. Third-party funders during this time adopted vocabulary from the banking world and started to identify themselves more with providers of non-recourse financing and, accordingly, started adapting third-party funding models on that basis. This allowed them to focus on wealthier claimants rather than access to justice or impecunious claimants. They sought to infiltrate corporate culture by promoting the advantages of financial risk transfer to commercial entities that did not need investment but that may choose it if the advantages in doing so could be justified not in terms of access to justice but in terms of bottom-line profitability. This period gave rise to financing solutions such as portfolio financing: the notion that a financial facility can be put in place across a claimant's portfolio of disputes or indeed a facility for a law firm to be used across multiple disputes. Third-party funders explained the benefits of their financing to corporate clients as one in which a legal department could be converted from a cost centre into a profit centre, and notions of shifting the costs of a dispute off the balance sheet sought to win over chief financial officers. For many, this was a rebalancing of what third-party funders should be a financial device, not a legal one. Disputes for funders could be seen as purely about compensation of loss without having to concern themselves with issues such as the dispensation of justice and the role funders play in either supporting, or in some jurisdictions running, claims. It was, like the commercial arbitration agreement, a private matter between commercial entities only.

This view of third-party funding as one chiefly about finance was born in the industry age as it pertains to international commercial arbitration and remains so today. It is perhaps best exemplified in the Essar Oilfield Services limited v. Norscot Rig Management Pvt Limited case (Essar v. Norscot).7 This was an International Chamber of Commerce (ICC) arbitration seated in London where Sir Philip Otto, sitting as sole arbitrator, allowed the victorious party to claim its third-party funding costs (including the funders' uplift) from the losing party. The award was challenged on this basis but upheld by the High Court of Justice by J Waksman QC on the basis that recoverable costs were broadly enough defined under the ICC 2012 Rules and the 1996 Arbitration Act that the arbitrator was permitted to do so. There are multiple procedural issues that relate to Essar v. Norscot, but from the perspective of third-party funder responsibility, the case is significant for two main reasons: (1) it reinforces the view that third-party funding is purely a financial device and, under the right conditions, recoverable on success; and (2) it raises issues of transparency and the effect of the presence of a third-party funder on all the parties to a dispute. The latter is of particular importance as it pertains to the third-party funder of investment treaty disputes, which dramatically increased in the post-industry age.

III The Post-Industry Age

i Third-party funding and ISDS

The second paradigm shift in third-party funding occurred nearly 10 years after Arkin with the now infamous Excalibur Ventures LLC v. Texas Keystone Inc and Ors, which was revisited more recently by the court of appeal in 2016. In this seminal case, Lord Justice Clarke drew a clear line between professional and ad hoc third-party funders. Weighing the benefits of access to justice against the potential for profiteering, his judgment was reassuring to some and a stern warning to others. In addition to confirming the Arkin cap, Clarke LJ inferred that if a third-party funder undertook proper due diligence to meet the claimant and to undertake the requisite assessment of the merits of a claim, it may be treated differently to those third-party funders that had abdicated responsibility and sought to treat a claim purely as an investment opportunity. The latter could be subject to costs orders on an indemnity basis. It imparted a sense of responsibility on third-party funders to be accountable for their investments. For some, Excalibur would discourage further investment in third-party funding and for others, as with Arkin, it provided additional clarity.

As a result, third-party funders began to distinguish themselves by those that had invested in the requisite skills and abilities to assess the merits of a claim, and those that were derided as being akin to gamblers, or ad hocs in the parlance of the growing third-party funding industry. Excalibur was the catalyst for the second paradigm shift that gave rise to the self-proclaimed professional third-party funder. Distinguishing between ad hoc and professional third-party funders, however, was unclear. At best, it seemed to be a distinction based on how many lawyers the third-party funder recruited. But, the focus on bringing on more disputes lawyers and the professionalisation of the industry brought disputes lawyers with ISDS experience another disputes market for third-party funders to expand into. During this age, third-party funders began more aggressively focusing on ISDS disputes.

Third-party funding of disputes did not start with ISDS but it has become the fastest growing dispute forum for third-party funders. The reasons for this are both qualitative and quantitative: ISDS is expensive (US$6.1 million per side in claimants' costs)8 and long (an average of 3.86 years to obtain an award, and an additional one to two years for post-award processes and enforcement).9 The ability to transfer the cost risk to a third party by sharing the upside in a potential award is obviously very attractive, but it was not obvious what the commercial terms of the funding agreement should be. ISDS was relatively untested at early stages of this post-industry age. As a result, what was typically seen in the industry was a reversion to pre-industry pricing revamped and referred to as risk pricing: this was merely a means by which a third-party funder could account for uncertainty by increasing profitability.

But the nature of ISDS disputes are qualitatively different to commercial arbitration. Where investors seek recourse for either the partial or wholesale destruction or expropriation without fair, prompt or adequate compensation of their investment, the loss suffered is often near complete. Third-party funding has its origins in access to justice for the impecunious, as explained above. When the wealthy ruling classes had such disproportionate influence that by their dealings they could destroy not just the transaction but the livelihood, the wealthy were practically above the rule of law, not least of which because of the high cost of access to justice. Investors and states have a similar inequality of arms inherent in the system (notwithstanding certain wealthy multinational companies), and as third-party funding was originally sought to balance the playing field in domestic litigation, it has readily been taken up by investor claimants in ISDS for the same reason.

Suddenly, at the ISDS level during this time, there were a plethora of task forces,10 white papers,11 practice directions12 and salient cases13 about or concerning third-party funders. For some, the issues relevant to domestic litigation where the nation state was involved in administering disputes pertaining to transparency and accountability became even more relevant when dealing with the nation state as a party to the dispute. From cases and developments, the dominant issues were those of provisional measures such as security for costs and confidentiality and transparency of the agreement with the third-party funder, as summarised below.

ii Security for costs

The ICSID Convention does not contain an express provision on security for costs and tribunals have tended to be reluctant on granting such orders.14 This restrictive approach has been maintained in various ICSID proceedings where third-party funders were involved. For instance, the arbitral tribunal in Commerce Group Corp and San Sebastian Gold Mines, Inc v. El Salvador15 maintained a restrictive approach to security for costs even when the proceedings were stayed while the applicants sought third-party funding. In the Order of the Committee Discontinuing the Proceeding and Decision on Costs, dated 28 August 2013, the tribunal ordered the claimants to pay the full administrative costs of the proceedings, but maintained its denial of security for costs.

The first known instance where an ISDS tribunal ordered security for costs where third-party funding was involved was the RSM Production Corporation v. Saint Lucia case, 13 August 2014,16 in which the tribunal ordered the claimant to pay security for costs in the amount of US$750,000 in the form of an irrevocable bank guarantee. However, that the claimant had obtained third-party funding was only used as a supportive argument not withstanding the separate 'assent' by Gavin Griffith who saw the ruling as confirmation that there should be automatic or near automatic security for costs where third-party funders are involved in ISDS cases. In contrast, the tribunal's reasoning did not show any such contempt for third-party funders, as the main and decisive reason for ordering security for costs was the claimant's proven history of defaulting on costs orders.

There have been subsequent decisions since RSM that have retained the same position in terms of a third-party funder's involvement and an applicant's request for security for costs.17

These early cases in the post industry age at the ISDS level as they relate to third-party funders suggest that tribunals are thus far inclined to maintain the status quo and to treat the advent of third-party funders in ISDS as nothing that would give rise to deviating from the long held view that security for costs applications should be allowed only in exceptional circumstances. However, there is a growing number of cases that suggest that future tribunals are prepared to investigate third-party funding arrangements more closely.

iii Confidentiality

ICSID tribunals have held that the parties themselves are not under a general duty of confidentiality, absent agreement to the contrary.18 In contrast, certain tribunals have highlighted the importance of limiting public discussion of the case to not disturb the proceedings.19 However, as non-parties to the arbitration agreement, third-party funders are not bound by any confidentiality duties flowing from that agreement. This was notably the case during the EuroGas Inc and Belmont Resources Inc v. The Slovak Republic case in which the respondent's request for a confidentiality order against the claimants' funder was reportedly rejected by an ICSID tribunal.

iv Conflicts of interest

Arbitral tribunals tend to set aside requests for disclosure of third-party funding agreements raised by respondents at the ISDS level. In Guaracachi America, Inc and Rurelec PLC v. The Plurinational State of Bolivia (2013), the tribunal decided not to order the production of the agreement or 'further documentation' because 'the applicable provisions governing conflicts of interest in the present proceedings do not foresee the production of document by the Parties but rather disclosure by the arbitrators upon becoming aware of circumstances that could create a conflict of interest'.20

Concerns for conflicts of interest where third-party funding is involved are usually raised by the non-funded party and often relate to potential funderarbitrator relationships. This issue is closely related to confidentiality, disclosure and transparency. For instance, in South American Silver Ltd (Bermudas) v. Plurinational State of Bolivia21 with respect to Bolivia's request to order South American Silver to disclose the identity of its third-party funder and to disclose the terms of the funding agreement, the claimant readily conceded on the former and the tribunal rejected the latter.22

During the Muhammet ap and Sehil Inaat Endustri ve Ticaret Ltd Sti v. Turkmenistan case,23 on 23 June 2014, the tribunal issued its Procedural Order No. 2 recording its decision on the respondent's request of 11 April 2014 for disclosure of the third-party funding agreement. The tribunal ruled as follows:

It seems to the Tribunal that the following factors may be relevant to justify an order for disclosure, and also depending upon the circumstances of the case:

a To avoid a conflict of interest for the arbitrator as a result of the third-party funder;

b For transparency and to identify the true party to the case;

c For the Tribunal to fairly decide how costs should be allocated at the end of any arbitration;

d If there is an application for security for costs if requested; and

e To ensure that confidential information which may come out during the arbitral proceedings is not disclosed to parties with ulterior motives.

Applying these factors, the tribunal was not persuaded that there was any reason to make an order requiring the claimants to disclose how they were funding the arbitration, but the factors listed do open the door to future rulings where such a disclosure can be made, and specifically the tribunal held that 'this decision does not preclude the respondent from making a further request for disclosure at a later stage in this arbitration if it has additional information to justify the application.'

Taken as a whole, these cases and developments as they pertain to security for costs, confidentiality and conflicts of interest at the ISDS level are strong evidence that the role of third-party funders is unlikely to be relegated to that of mere financial services providers. Questions of transparency and legitimacy will continue to be probed, and, as a consequence, the type of third-party funder, how they conduct themselves, and from where and how they have raised their money are likely to be of greater relevance in the modern age.

IV The Modern Age

We are currently in what appears to be the third paradigm shift of third-party funding the modern age. There are today two prevailing and competing models of 'professional' third-party funders: risk pricing versus merits-based models. The former dictates that most claims can be funded if the terms are right and adheres to the view that third-party funders are mere providers of bespoke financial products. By this logic, even Excalibur could have been funded providing the commercial terms of the investment were sufficiently high to justify the risk. The reason for this is that the risk pricing model considers awards and judgments only in terms of compensation of loss and thus there is nothing wrong in funding an unmeritorious claim if the potential for a windfall is possible. This is the same mentality that characterises many financial markets where higher risks equate to higher rewards.

In contrast, the merits-based model requires the funder to treat a judgment or award as more than just an investment opportunity and a commodity to be invested in. It dictates that an award is first and foremost a judicial instrument for the dispensation of justice. The compensation of loss is as a result of the dispensation of justice, and thus knowingly funding an unmeritorious case or not accepting responsibility to assess the merits can and arguably should expose the funder to a costs liability.

If the battle between these two competing models continues unchecked, it is likely that the risk pricing model will prevail. The reasons for this are particular to our times as third-party funding presents, for many potential investors in third-party funding, an uncorrelated asset class and thereby an attractive investment during times of financial market instability. As a consequence, a new crop of would-be funders have come to the market having raised funds with promises of windfall returns to their investors. They were able to do so because despite the first two paradigm shifts, the third-party funding industry standard terms have barely changed in nearly 15 years. They continue to equate to three times or 30 per cent, whichever is the greater. This is surprising because the greater of three times or 30 per cent of the total value of the asset in private equity or asset management terms represents a windfall return unheard of in most markets, except in very high-risk categories. However, most self-proclaimed professional third-party funders report win rates that are between 80 and 90 per cent, or more. If terms such as three times the investment or 30 per cent of the value of the dispute have been historically justified to claimants and law firms on the basis that investment in disputes is high-risk, it is a statement at odds with the reported reality by mainstream third-party funders. Consequently, in the absence of defining cases for this third paradigm shift, the risk pricing model is likely to prevail because funders are readily able to raise new, albeit expensive, money on the basis of an industry standard of three times or 30 per cent return on investment, which could arguably allow funders to lose 7080 per cent of the claims they invest in and still generate profits for their investors.

However, this current paradigm shift, characterised by the battle between the risk pricing and merits-based models of third-party funding, is not devoid of indicators as to how it may develop. Consistent with the previous two paradigm shifts, in 2016 the UK Court of Appeal upheld Clarke LJ's judgment on Excalibur and, therefore, the merits-based model that encourages thorough due diligence prior to funding a claim, and ongoing and effective monitoring during the life of the dispute. Furthermore, in Bailey v. GlaxoSmithKline UK Ltd [2017] Justice Foskett effectively considered the nature of the funder involved and decided that the Arkin cap could be lifted if not doing so would lead to an injustice. These advancements in case law at the domestic litigation level in countries such as the United Kingdom are likely to help shape the development of the role of the third-party funder at the ISDS level because of the one common denominator the nation state. Where public money is involved, whether by administering a dispute or participating in it, questions will be asked about whether third-party funders are adopting a risk pricing model that may well give rise to more and greater disputes of questionable merit in search of windfall returns regardless of the cost to the public, or whether funders will be compelled to adopt a merits-based model where funders scrutinise more and temper returns on investment.

The differences between funders is greater today than their similarities. Some funders are publicly listed,24 some have front offices regulated by financial authorities25 and at least one has set up regulated asset management funding vehicles for the specific purpose of funding disputes.26 However, the vast majority and some well-known third-party funders appear to opt for a form of self-regulation with no oversight or transparency on conduct, how money is raised or from where.27 Tribunals in ISDS cases are likely to be put under more pressure to probe further not only into who the third-party funder to an ISDS dispute is, but also how much control it is exerting over the dispute. So far, tribunals have mostly been reluctant to inspect the workings of the funding agreement. Instead, they tend to prefer to focus on who the funder is for the purpose of conflicts of interests with the tribunal. However, it is not inconceivable that at some point during the modern age, if third-party funding remains an unregulated activity, tribunals will more frequently seek to inspect funding agreements to determine whether the funder has subrogated any of the rights typically reserved for the claimant. In the absence of an ability to develop an equivalent to the Arkin cap principle, ISDS tribunals may more frequently render orders for provisional measures such as security for costs.28 As a counterbalance, such a development may lend greater weight to arguments that the costs of such security should be recoverable from the respondent if the claim ultimately prevails.

Some jurisdictions have already taken the view that third-party funding needs greater oversight and control. In the United Arab Emirates, the Dubai International Financial Centre has created a practice direction specifically for third-party funding. Regulation is currently being considered in Abu Dhabi. In Singapore and Hong Kong, third-party funding regulations have now been enacted. In Australia, there has more recently been a call for the licensing of third-party funders. These steps all precede what is widely expected to be a change in the ICSID rules in respect of third-party funding. The evolution of the third-party funder from litigation through commercial arbitration to ISDS has brought with it a desire for greater oversight and control of third-party funding. The question is what type of regulation negative (responding to a problem) or positive (ensuring access to third-party funding) will prevail? It is submitted that the answer lies in the type of third-party funder and the third-party funding model that prevails between risk pricing or merits-driven models as it pertains to ISDS.

Footnotes

1 Iain C McKenny is a director at and co-founder of Profile Investment.

2 See first table footnote.

3 https://www.jstor.org/stable/25746092?seq=1#page_scan_tab_contents.

4 http://arbitrationblog.kluwerarbitration.com/2017/02/02/third-party-funding-milan-event-offered-view-ahead.

5 Ceskoslovenska obchodni banka, a.s. (CSOB) v. Slovak Republic, ICSID Case No. ARB/97/4, Decision of the Tribunal on Objections to Jurisdiction (24 May 1999).

6 This is not to suggest that third-party funding brokers did not exist prior to this time but merely that by this time there were established third-party funders, and therefore brokers who catered for them.

7 http://arbitrationblog.kluwerarbitration.com/2016/10/15/the-essar-v-norscot-case-a-final-argument-for-the-full-disclosure-wingers-of-tpf-in-international-arbitration/.

8 In 2012, the OECD concluded that legal and arbitration costs for claimants and respondents in recent ISDS cases averaged in excess of US$8 million, having surveyed 143 ISDS awards (available as of August 2011). In 2013, UNCTAD reported that legal fees and tribunal expenses, on average, 'exceeded $8 million per party per case'. In 2014, an Allen & Overy study concluded that average party costs were US$4,437,000 for claimants and US$4,559,000 for respondents based on a review of 176 ISDS awards (available as of December 2012). In 2015, the European Commission suggested in a paper entitled 'ISDS: some facts and figures' that 'the average legal and arbitration costs for a claimant are around $8 million'.

9 Procedural Issues in International Investment Arbitration, J Commission and R Moloo, March 2018, appendix 9.

10 The ICCA-Queen Mary Task Force on Third-Party Funding is a joint task force established by ICCA and Queen Mary, University of London in 2013. https://www.arbitration-icca.org/media/10/40280243154551/icca_reports_4_tpf_final_for_print_5_april.pdf.

11 In Hong Kong, the Commission issued two reports after consultations, in October 2015 and October 2016, which culminated in proposed legislative amendments to Hong Kong's Arbitration Ordinance, as well as proposed amendments to associated regulations. In Singapore, the consultations carried out by the Ministry culminated in two proposed draft instruments: the Civil Law (Amendment) Bill 2016 and the Civil Law (Third Party Funding) Regulations 2016.

12 The author assisted in the drafting of the first practice direction developed by the Dubai International Financial Centre on third-party funding. https://www.difccourts.ae/2017/03/14/practice-direction-no-2-2017-third-party-funding-difc-courts/.

13 There are several examples of investorstate arbitration cases where third-party funders have been involved. Among the more high-profile is the Canadian mining company, Crystallex, which was awarded over US$1.38 billion in a claim against Venezuela in which Crystallex was supported by third-party funders. More recently, Eco Oro, having filed an ICSID arbitration under the CanadaColombia Free Trade Agreement relating to the Angosutra gold and silver deposit in the country's Andean region, has the backing of third-party funders.

14 See Libananco Holdings Co. Limited v. The Republic of Turkey, Decision on Preliminary Issues, ICSID Case No. ARB-06-08, 23 June 2008.

15 Commerce Group Corp. and San Sebastian Gold Mines, Inc. v. The Republic of El Salvador, ICSID Case No. ARB/09/17 (Annulment Proceeding), Decision on El Salvador's Application for Security for Costs of 20 September 2012.

16 RSM Production Corporation v. Saint Lucia, ICSID Case No. ARB/12/10, Decision on Saint Lucia's Request for Security for Costs, 13 August 2013.

17 Other cases that have cited RSM in matters of security for costs and third-party funding: Sergei Viktorovich Pugachev v. Russian Federation, UNCITRAL, Interim Award, 17 July 2017; Eskosol S.p.A. in liquidazione v. Italian Republic, ICSID Case No. ARB/15/50, Procedural Order No. 3 (Decision on Respondent Request on Provisional Measures), 12 April 2017; Interocean Oil Development Company and Interocean Oil Exploration Company v. Federal Republic of Nigeria, ICSID Case No. ARB/13/20, Procedural Order No. 6 Decision on the Respondent Application for Provisional Measures, 1 February 2017; Dawood Rawat v. Republic of Mauritius, PCA Case No. 2016-20, Order Regarding Request for Interim Measures, 11 January 2017; Lighthouse Corporation Pty Ltd and Lighthouse Corporation Ltd, IBC v. Democratic Republic of Timor-Leste, ICSID Case No. ARB/15/2, Procedural Order No. 2 for Provisional Measures, 13 February 2016; Lao Holdings N.V. v. Lao People's Democratic Republic II, ICSID Case No. ARB(AF)/16/2, Procedural Order No. 6, 26 July 2018.

18 See, for instance, in Amco Asia Crop. & Others v. Republic of Indonesia, ICSID Case No. ARB/81/1, Decision on Request for Provisional Measures of 9 December 1983: 'as to the spirit of confidentiality of the arbitral procedure, it is right to say that the Convention and the Rules do not prevent the parties from revealing their case'; and Biwater Gauff (Tanzania) Ltd. v. United Republic of Tanzania, ICSID Case No. ARB/05/22, Procedural Order No. 3 of 29 September 2006 (paras. 114-121).

19 The Loewen Group Inc. and Raymond L. Loewen v. United States of America, ICSID Case No. ARB(AF)/98/3, Decision on hearing of Respondent's objection to competence and jurisdiction of 5 January 2001.

20 Guaracachi America, Inc. and Rurelec PLC v. The Plurinational State of Bolivia, PCA Case No. 2011-17, Procedural Order No. 13 (21 February 2013).

21 South American Silver Ltd (Bermudas) v. Plurinational State of Bolivia, UNCITRAL, PCA Case No 2013-15, Procedural Order No. 10 (11 January 2016).

22 'The Tribunal considers that while the existence of a third-party funder may be an element to be taken into consideration in deciding on a measure as the one requested by Bolivia, this element alone may not lead to the adoption of the measure . . . the disclosure of the name of the funder, the Tribunal considers that, for purposes of transparency, and given the position of the Parties, it must accept Bolivia's request of disclosure of the name of SAS' funder. Finally, concerning the disclosure of the terms of the financing agreement entered into with the third-party funder, the Tribunal will reject such request. In the Tribunal's opinion, there is basis to order the disclosure of the name of the third-party funder, but not to order the disclosure of the agreement entered into with the third-party funder.' (Paras. 75-84).

23 Muhammet ap and Sehil Inaat Endustri ve Ticaret Ltd. Sti. v. Turkmenistan (Decision on Respondent's Objection to Jurisdiction under Article VII(2) of the Turkey-Turkmenistan BIT).

24 e.g., IMF Bentham, Burford Capital.

25 e.g., Augusta Ventures, Harbour Litigation Funding and, until the recent decision to cease trading, Calunius.

26 Profile Investment, https://globalarbitrationreview.com/article/1176253/a-new-fully-regulated-third-party-funder-opens-in-paris.

27 The Association of Litigaiton Funders is the most well-known example of a self-regulating body owned and controlled by the members it regulates.

28 In 2017, Burford Capital's role as funder of a pair of treaty claims against Pakistan worth US$640 million ended with the claimants being ordered to pay around 11 million in costs; Vannin Capital's role in financing a US$100 million DR-CAFTA claim against Costa Rica ended in a victory for the state and a US$1 million costs award against the claimant. At the time of writing, in Italba Corporation v Oriental Republic of Uruguay (ICSID Case No. ARB/16/9), the state prevailed leaving a cost awards against the claimant who was funded by IMF Bentham for US$5.9 million.

Read the original:

Evolution of the Third-Party Funder - Lexology

Check Out The BMW Kidney Grille’s Evolution Over 87 Years – Motor1

BMW's kidney grille is such a distinctive design element of the brand's models that it's hard to picture a product from the company without these dual openings at the front. It's now an iconic element for the firm's styling.

The famous design detail has changed many times since 1933, and it has only become bigger and bigger in recent years. Just look at the forthcoming BMW 4 Series for the best example.

But where does the BMW "double kidney" come from and how has it evolved over the years? Let's find out together!

A brief historical note is necessary because when the BMW 303 was born in 1933, the double kidney was nothing more than a radiator grille divided into two long vertical parts that angled rearwards on the outside.

Designer Fritz Fielder used this split design as a way to improve the 303's aerodynamics. His decision kicked off a legend that has continued to appear on BMW's machine. Over time, the iconic grille has changed in height, width, shape, and position, but those who see it know at a glance that the car is a BMW.

The BMW 328 was among the cars that first made the BMW brand (and its grille) known in Europe because of its success in racing.

The style became more famous on the luxurious 327, and the look remained largely intact through the 1940s. In the postwar period, there were the 501 and 502 models that reproduced kidneys with a few changes. On the 503, things started to change when the shape shrunk in height.

In 1956, the 507 brought a complete revolution to the kidney grille. The spectacular sports car with a design by Albrecht von Goertz boasted a pair of short, yet wide horizontal opening that created an integral part of the styling between the headlights.

TheBMW Z8 with a design by Henrik Fisker underthe supervision of Chris Bangle brought the 507's styling back with a more modern appearance. The similarities are obvious, yet don't go so far to make the Z8 look too retro.

In recent years, BMW's designers have tweaked the design to incorporate a horizontal line joining the headlights to the grille. You can see this element on the latest3 Series, 5 Series, and 8 Series. The i3 adapts this look into a smaller size because it does not need air to flow to the engine. With the i8 and latest Z4, the firm stretched the shape to occupy a larger horizontal area of the front end.

The 2011 BMW Vision ConnectedDrive and 2019 BMW Vision M NEXT concepts follow this same general style. However, the designers put a focus on creating more complex polygonal shapes along the edges.

Returning to the earlier evolution of the kidneys, check out look the arrival of the so-called Neue Klasse models in the early 1960s. On these vehicles, the designers used two relatively skinny ovals in the center and incorporated a wide array of mesh outward to the headlights.

The first 5 Series from 1972, the 1975 3 Series, and the 1977 7 Seriesfurther crystallized this distinctive aspect of BMW's frontal design for the decades to come.The general concept of this styling cue lasted until the mid-1990s on some of the brand's machines.

Even while the company's major models wore the trademark combination of a wide grille opening and circular headlights, other products showed experimentation with something different. Vehicles like the M1, Z1, and original 8 Series still had kidneys, but they were smaller and simpler than other members of the lineup.

The 1989 Z1 and 1990 8 Series actually previewed the future direction for the kidneys that later models adopted. In the 1990s, vehicles like the E36-generation 3 Series, E39-gen 5 Series, and much of the rest lineup no longer head the wide grille from the past decades. Instead, the kidneys were a discreet element of the nose, and body-color elements surrounded them.

This styling cue continued into the 2000s on vehicles like the 1 Series, 6 Series, X1, and X3.

Over the past ten years, BMW teased the motoring world by showing concepts and even some production cars with an slightly evolved take on the kidney grille.

With the 2018 BMW X5, the designers enlarged the openings horizontally and vertically. Using chrome for the uprights made them even more visually distinctive. So far, the 2019 7 Series and X7 are the most obvious expressions of this styling cue, but we know that more models like this are on the way.

Before that, however, there was the 2013 BMW Pininfarina Gran Lusso Coupe Concept and the 2014BMW Vision Future Luxury were hints of what was to come.

In 2011, the BMW 328 Hommage concept debuted showing a modern take on the classic model. Part of its design was a large, vertical grille that ran from the tip of the hood nearly to the ground. With the upcoming 4 Series, we are seeing the company incorporate this cue into a production vehicle.

The 2014 BMW 3.0 CSL Hommage, followed by the 2016 Vision Next 100, 2019 Concept 4, and2020 Concept i4highlighted the slow evolution of BMW designers incorporating the taller kidney grille into increasingly production-ready-looking vehicles. We now know the Concept 4 is a very close preview of what to expect from the next-gen 4 Series when it arrives in showrooms.

Even earlier, there were signs of BMW eliminating the gap between the kidneys and using a single bar between them instead. Vehicles like the 2017 Vision Dynamics,2017 Vision iNEXT and 2018 Concept iX3 showed this evolution.

While they are uncommon, there are BMWs without a kidney grille. The Isetta comes to mind, although it's styling originally comes from an Italian microcar. There's also the BMW 700 that has a rear-engine layout, so the kidneys aren't a styling necessity.

Here's where things get weird because there are vehicles with close relationships to the Bavarian automaker without actually being BMW products that have a kidney grille. First, there'sEisenacher Motorenwerk (or EMW) from the former East Germany. Following World War II, the former BMW factory in Eisenach, Germany, began re-manufacturing pre-war BMW vehicles and later some tweaked versions of these products.

There's also the case of Britain's Bristol Cars in the post-war period. It was able to gain access to BMW technology and even employed BMW 303 designersFritz Fielder to create the Bristol 400 that had a striking styling similarity to pre-war BMW vehicles.

There have also been a few cases of designers wanting to tweak the kidney grille. For example, the Spicup concept (green vehicle below) by Bertone in 1969 opted for an angular shape with rectangular shapes, which wasn't on production BMW vehicles at the time although was somewhat simpler to the later M1. Bertone also created the Garmisch (the beige vehicle below) with a diamond-shaped take on the kidneys.

View original post here:

Check Out The BMW Kidney Grille's Evolution Over 87 Years - Motor1

Algorithm Developed to Predict the Evolution of Genetic Mutations – SciTechDaily

The algorithm called minimum epistasis interpolation results in a visualization of how a protein could evolve to either become highly effective or not effective at all. They compared the functionality of thousands of versions of the protein, finding patterns in how mutations cause the protein to evolve from one functional form to another. Credit: McCandlish lab/CSHL, 2020

Quantitative biologists David McCandlish and Juannan Zhou at Cold Spring Harbor Laboratory have developed an algorithm with predictive power, giving scientists the ability to see how specific genetic mutations can combine to make critical proteins change over the course of a species evolution.

Described in Nature Communications, the algorithm called minimum epistasis interpolation results in a visualization of how a protein could evolve to either become highly effective or not effective at all. They compared the functionality of thousands of versions of the protein, finding patterns in how mutations cause the protein to evolve from one functional form to another.

Epistasis describes any interaction between genetic mutations in which the effect of one gene is dependent upon the presence of another. In many cases, scientists assume that when reality does not align with their predictive models, these interactions between genes are at play. With this in mind, McCandlish created this new algorithm with the assumption that every mutation matters. The term Interpolation describes the act of predicting the evolutionary path of mutations a species might undergo to achieve optimal protein function.

The researchers created the algorithm by testing the effects of specific mutations occurring in the genes that make streptococcal GB1 protein. They chose the GB1 protein because of its complex structure, which would generate enormous numbers of possible mutations that could be combined in an enormous number of possible ways.

Because of this complexity, visualization of this data set became so important, says McCandlish. We wanted to turn the numbers into a picture so that we can understand better what [the data] is telling us.

The visualization is like a topological map. Height and color correlate with the level of protein activity and distance between points on the map represents how long it takes for the mutations to evolve to that level of activity.

The GB1 protein begins in nature with a modest level of protein activity, but may evolve to a level of higher protein activity through a series of mutations that occur in several different places.

A photo of David McCandlish in his office. He is pointing to a visualization of what he calls the protein GB1s evolutionary space. Credit: CSHL, 2020

McCandlish likens the evolutionary path of the protein to hiking, where the protein is a hiker trying to get to the highest or best mountain peaks most efficiently. Genes evolve in the same manner: with a mutation seeking the path of least resistance and increased efficiency.

To get to the next best high peak in the mountain range, the hiker is more likely to travel along the ridgeline than hike all the way back down to the valley. Going along the ridgeline efficiently avoids another potentially tough ascent. In the visualization, the valley is the blue area, where combinations of mutations result in the lowest levels of protein activity.

The algorithm shows how optimal each possible mutant sequence is and how long it will take for one genetic sequence to mutate into any of many other possible sequences. The predictive power of the tool could prove particularly valuable in situations like the COVID-19 pandemic. Researchers need to know how a virus is evolving in order to know where and when to intercept it before it reaches its most dangerous form.

McCandlish explains that the algorithm can also help understand the genetic routes that a virus might take as it evolves to evade the immune system or gain drug resistance. If we can understand the likely routes, then maybe we can design therapies that can prevent the evolution of resistance or immune evasion.

There are additional potential applications for such a predictive genetic algorithm, including drug development and agriculture.

You know, at the very beginning of genetics there was all this interesting speculation as to what these genetic spaces would look like if you could actually look at them, McCandlish added. Now were really doing it! Thats really cool.

Reference: Minimum epistasis interpolation for sequence-function relationships by Juannan Zhou and David M. McCandlish, 14 April 2020, Nature Communications.DOI: 10.1038/s41467-020-15512-5

Read this article:

Algorithm Developed to Predict the Evolution of Genetic Mutations - SciTechDaily

The Evolution of Xbox Controllers From The Original Xbox To Xbox Series X – GamingBolt

The late 90s were a harrowing time. Fresh off the success of the PlayStation One, Sony were already making plans for the PlayStation 2 to also dominate the market. The Nintendo 64 was at the end of its life cycle with the company shifting away from cartridges for in the GameCube. Segas Dreamcast was still a thing but facing severe issues due to a lack of advertising and support, not to mention general disagreement among company executives. We all know what happened though Sega would discontinue the console and bow out of the hardware market entirely in March 2001.

However, slightly before that, an unlikely competitor appeared. After years of rumors, Microsoft finally announced its console gaming plans and revealed the Xbox prototype at GDC 2020. While theres a lot to say about the consoles development history, were going to focus on the controller which also debuted at GDC. Put simply, it was horrible.

Lets back up a bit though. The Xbox controller was designed by developer Seamus Blackley and given the nickname Duke by hardware project manager Brett Schnepf. However, it would be its other nickname, Fatty, which would stand out a lot more on release. Despite several similarities with the DualShock 2 (like rumble support), the Xbox controller had a number of unique features. Along with the standard four face buttons, fashioned after Nintendos X, Y, A and B button setup, the console had two more buttons sitting above them one black, the other white.

There were Start and Select buttons but these were placed near the bottom of the controller, right between the digital D-Pad and right analog stick. The left analog stick was instead positioned to the far left edge and in the middle was a massive emblem with the Xbox name and logo in black and green. Two triggers rested on the back with no shoulder bumpers. One neat feature was the controllers cable having dongles that could break away, mitigating any danger that tripping would have caused for the console.

Overall, the design of the Xbox controller was weird when compared directly to the DualShock 2 but not completely out of this world. The real problem was its size and build. It was massive, about three times that of Sonys controller, and seemed more suited to large hands (and even then, it was pushing its luck). According to Blackley, the disdain for the controller was such that he had things thrown at me on stage. The build quality wasnt much better, being viewed as cheap by different outlets.

A lot of the controllers footprint was due to the circuit board design though. At the time, Microsoft wanted a folded and stacked design akin to the DualShock 2. Unfortunately, its supplier, Mitsumi Electric, refused and thus went with the Duke design. There was some redemption on the horizon though. When the Xbox came to Japan in February 2002, it sported the smaller, more comfortable Xbox Controller S (audiences in that region were spared of the Dukes presence, for the better). Microsoft would eventually bring the Controller S to Western audiences, replacing the original Duke in standard packages by 2002 in the US and 2003 in Europe.

The Controller S had a much more positive response and its easy to see why. Besides the more compact design, the Xbox Controller S sports a much less obnoxious Xbox emblem on the front, smaller handles, re-positioned black and white buttons, and the lack of a big gulf between the D-pad and right analog stick. Though the placement of the Start and Select buttons was strange, situated to the bottom of the left analog stick, the Controller S felt better to hold and use. The Duke still remained an option for those who wanted it but the Controller S was the new standard.

Microsoft recognized this as it prepared for the next console generation. Thanks to the advantage of launching the Xbox 360 one year before the PlayStation 3 (which had other unfortunate consequences for the consoles quality), it didnt falter when it came to the controller. Taking many design notes from the Xbox Controller S, the Xbox 360 controller streamlines things further. The Xbox emblem on the front was gone, replaced with a smaller button with the Xbox Logo called the Guide button.

The black and white buttons were gone with the Select button being replaced by the Back button, which is now positioned next to the Guide button along with the Start button. Shoulder buttons were added though the layout in terms of face buttons, analog sticks, D-Pad and triggers was more or less the same as the Controller S. The Guide button was perhaps one of the better new additions. Besides opening up the new Guide menu which allowed for messaging, voice chat and other functions without leaving the game it would light up different sections of its ring when multiple controllers were connected. This helped denote player 1, player 2 and so on.

Microsoft also added a serial connector on the bottom on the controller, which could be used to attach a chat-pad, while the top sported a 2.5 mm TRS connector where headsets could be connected. The controller also had a wireless variant that worked with batteries or a rechargeable battery pack, but could still be connected to the console via USB cable.

All in all, the reception to the Xbox 360 controller especially following the dismal Duke was positive all-around. One nice added function of the controller was that it could be connected to ones PC, which used the Microsoft XInput interface library for playing different titles. Whether it was known or not, this would have a significant impact on controller usage with PC games for years to come, providing a great controller solution to PC players everywhere that balanced quality with price.

In 2010, the Xbox 360 wireless controller received a variant design with the Play and Charge Kit. This allowed for switching out the D-pad and going with either the traditional plus-shaped design or the more circular shape. Though it didnt seem like a big deal back in the day, this would be a precursor to the customization introduced in the Xbox Elite Wireless Controller. Other controllers with transforming D-pads would be released, usually as limited edition products for certain games like Gears of War, Call of Duty: Modern Warfare 3 and Halo 4. Why, especially when these games were more known for aiming with analog sticks? Well, why not?

So everything was going hunky dory for Microsoft, despite the Xbox 360 winding down in the number of high-profile exclusives and hardcore gaming titles at the end of its lifespan. Fortunately, the company was already prepping for the next generation of consoles.

Unfortunately, it would screw up the messaging for the Xbox One something fierce, outlining always-online functions, increased Kinect functionality and way too much emphasis on being an all-in-one media solution (before backtracking on almost everything just months before release). While the numerous problems with the console have been documented endlessly over the years, the Xbox One controller proved itself to be one of the most solid controllers till date.

The overall shape of the controller feels better thanks to changes in the grips, a more premium finish and curved bumpers and triggers. The button layout remained the same, right down to the D-pad which was changed to a more traditional design for better performance in fighting games and analog sticks.

Some notable differences include the Guide button being near the top of the controller and lacking the light-up quadrants that could distinguish other players; the removal of the Start and Select buttons in favor of the Menu and Guide buttons; and rumble motors within the triggers which could provide for specific feedback. One could essentially have a single trigger or both provide rumble feedback, allowing for some customization of the haptic feedback experience. Its crazy to think that Microsoft spent over $100 million developing the Xbox One controller but the effort clearly shows.

Though Microsoft would provide a slight revision in 2015, with a headphone jack at the bottom and enabling wireless firmware updates, a much bigger variant was announced with the Xbox One Elite Wireless controller. Marketed as a premium device for the elite gamer, it sported an insane amount of customization.

It was possible to swap out the analog sticks and D-pad, featured interchangeable paddles on the back that could be assigned different button functions and hair trigger locks that reduced the distance required for presses. And if you really wanted to go crazy with the setup, it was possible to fully customize all the buttons, trigger and analog stick sensitivity, the whole works. You could even save two different profiles for buttons and switch between them when required.

Despite its high cost ($150 at launch), the Xbox Elite Wireless Controller was a pretty strong success. Interestingly, it faced a number of different issues upon launch like the build quality not being up to par, the bumpers not working properly and so on. Microsoft seemingly fixed these issues or at least replaced the faulty controllers. This wouldnt be the last time that an Elite Wireless Controller would be subject to hardware issues.

Less elite gamers werent left out in the cold that year, thankfully. A slightly less crazy revision of the default controller came in 2016, coinciding with the launch of the Xbox One S. The Model 1708 supported Bluetooth and textured grips which was nothing too drastic but provided decent improvements over an already stellar controller.

By 2018, leaks suggested that an Elite Wireless Controller Series 2 was on the way. The controller would be officially revealed at E3 2019 with a cost of $179.99. In terms of features, it went even further beyond than its predecessor, sporting an internal rechargeable battery with up to 40 hours of life, a rubberized grip that wrapped around the controller, more variety in the interchangeable thumb-sticks and paddles, a tool for adjusting the thumb-sticks, Bluetooth support and a USB-C connector. Better trigger grips, revamped bumpers, up to three custom profiles and one default profile that could be switched at will Microsoft spared no expense to make the Elite Wireless Controller Series 2 stand out.

Which is a shame because after its launch in November 2019, some users began reporting a number of issues. Unresponsive face buttons, connectivity issues, drifting with the analog stick it felt like the original Elite Wireless Controller all over again, except with the caveat of having to pay more. Microsoft was noted to be actively investigating issues with its teams and encouraged consumers to contact Xbox support. For the time being, at least, these issues seem to have been resolved and the Elite Series 2 remains one of the more popular accessories in the US market.

With the Xbox Series X releasing in holiday 2020, Microsoft has taken to implementing a number of the Elite Wireless Controllers features into the base Xbox One controller. This includes the D-pad, which incorporates a deeper center for resting ones thumb, and a more premium feel overall. The standard face buttons return along with two triggers and bumpers, though the triggers are more rounded this time. The signature guide button is no longer in its own separate section at the top but melded into the rest of the controller.

In terms of ergonomics, the grips are more sculpted. The overall size was created with an eight-year olds hands in mind to allow for a wider selection of players to comfortably use it. Throw in support for Bluetooth Low Energy to pair with mobile devices and other hardware (while also remembering the different devices it pairs with) along with a USB-C port for charging. Finally, theres the Share button just beneath the View and Menu buttons for capturing and sharing screenshots and clips, much like on the DualShock 4. Microsoft has yet to reveal the quality of clips and screenshots that can be captured though. Sadly, theres no internal rechargeable battery like the Elite Series 2 but such battery packs will be available separately.

The Xbox franchise hasnt existed as long as other consoles but its still managed to hold its own through the various ups and downs. Despite an unequivocally terrible controller for the original Xbox and issues with the Elite Wireless Controller series, Microsoft has provided quality devices for each generation, catering to both the casual and premium ends of the market while offering a healthy amount of color customization.

Its kind of ironic that while Sony, known for sticking to a traditional design with its DualShock series, has diverged into something new altogether, Microsoft is being more conservative in its design philosophy. Whether it will lead to a better performing controller, especially given the lack of any major bells and whistles (at least at this stage), remains to be seen. Nevertheless, were looking forward to getting our hands on it and seeing how a potential Elite series could pan out in the long run. If nothing else, we can be assured of another top-performing controller for PC titles in the coming years.

Read the original:

The Evolution of Xbox Controllers From The Original Xbox To Xbox Series X - GamingBolt